Don’t you love the smell of a corporate takeover right after legacy brand portfolios experience cycles of weakness? On April 16, the board of directors of Science in Sport released a statement that confirmed it had received a possible takeover offer from the private equity firm bd-capital. Moreover, it noted that discussions were at an advanced stage…but there could be no certainty that a firm offer (with acceptable terms) will be made. But then about 24 hours after the takeover interest emerged, the legacy sports nutrition brand portfolio announced that it reached agreement on the terms of an all-cash acquisition by bd-capital. But while Science in Sport and PhD Nutrition are still two highly regarded supplement brands, the relentless pursuit of top line growth, during primarily the “Great Shutdown” era, led to some poor historic strategic decisions and an inflated operating structure. So, in the latter portion of 2023, Science in Sport established a new leadership team, performed a full business review, and reset strategic focus. And while these tough strategic decisions provided a more stable platform for future growth, and Science in Sport saw both operational and financial performance improvements…revenue did decline 17.5% YoY to around $69 million in 2024. And based on the Science in Sport Plc closing share price on April 15, the takeover offer by bd-capital represented a 24% premium…valuing the company at about $109 million. But while revenue and EDITDA multiples are a bit wonky, I’d suggest judging the purchase price beyond a set of financial metrics. Firstly, Science in Sport isn’t the typical supplement company found everywhere within the U.S. market that deploys an “asset light business model” and essentially is a marketing company. In fact, three years ago, Science in Sport invested ~$10 million to build a state-of-the-art consolidated manufacturing and logistics hub. Next, the private equity firm had closely followed Science in Sport for several years…and believed the declining revenue period presented an opportunity to acquire two strongly positioned sports nutrition brands. And since Science in Sport is within the early stage of a strategic reset, bd-capital likely established enough confidence in early turnaround indicators, that along with its operator-led investment model, sector-specific expertise to support the development of the business (it also owns Symprove and Bonusan), and access to additional capital…could unlock growth potential over a reasonable timeframe. But then, the final portion on my latest first principles content will predict how bd-capital will unlock this next phase of Science in Sport Plc growth potential? And this includes the taking full advantage of the growing endurance nutrition niche of the supplement industry, geographical expansion, and omnichannel footprint expansion. Lastly, I’m fully aware that this corporate takeover isn’t the largest, but at just over the $100M mark…it arguably represents a more typical exit event size (especially for a legacy sports nutrition brand portfolio that doesn’t generate the bulk of its sales activity from functional foods and/or functional beverages). Unfortunately, the recent collection of billion-dollar M&A transactions, that involved brands that were incubated within the supplement industry, has started to wrongfully set an expectation of what success looks like. So, while those M&A transactions should be applauded…don’t miss other categorical learning opportunities (like this one) by only obsessing over outliers.